Genetic Variants Associated With Drug-Induced Hypersensitivity Reactions: towards Precision Medicine?

[1]  Yen‐Hua Huang,et al.  Whole Genome Sequencing Identifies Genetic Variants Associated with Co-trimoxazole Hypersensitivity in Asians. , 2020, The Journal of allergy and clinical immunology.

[2]  Tae-Gyun Kim,et al.  Application of single-cell RNA sequencing on human skin: Technical evolution and challenges. , 2020, Journal of dermatological science.

[3]  T. Profaizer,et al.  Clinical utility of next generation sequencing based HLA typing for disease association and pharmacogenetic testing. , 2020, Human immunology.

[4]  S. Benjaponpitak,et al.  Association of HLA genotypes with phenytoin induced severe cutaneous adverse drug reactions in Thai children , 2020, Epilepsy Research.

[5]  I. James,et al.  New genetic predictors for abacavir tolerance in HLA-B*57:01 positive individuals. , 2020, Human immunology.

[6]  W. Aekplakorn,et al.  Genetic Diversity of HLA Class I and Class II Alleles in Thai Populations: Contribution to Genotype-Guided Therapeutics , 2020, Frontiers in Pharmacology.

[7]  M. Mack,et al.  A precision medicine–based strategy for a severe adverse drug reaction , 2020, Nature Medicine.

[8]  H. Kong,et al.  Targeted therapy guided by single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report , 2020, Nature Medicine.

[9]  P. Demoly,et al.  Genetic variants associated with T cell–mediated cutaneous adverse drug reactions: A PRISMA‐compliant systematic review—An EAACI position paper , 2020, Allergy.

[10]  M. Relling,et al.  The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later , 2019, Clinical pharmacology and therapeutics.

[11]  P. Demoly,et al.  Towards a more precise diagnosis of hypersensitivity to beta‐lactams — an EAACI position paper , 2019, Allergy.

[12]  Javier Martín,et al.  GNAI2 variants predict nonsteroidal anti‐inflammatory drug hypersensitivity in a genome‐wide study , 2019, Allergy.

[13]  H. Muktar,et al.  Absence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: Implications for use of abacavir , 2019, The Nigerian postgraduate medical journal.

[14]  M. Blanca,et al.  Identification of Novel Biomarkers for Drug Hypersensitivity After Sequencing of the Promoter Area in 16 Genes of the Vitamin D Pathway and the High-Affinity IgE Receptor , 2019, Front. Genet..

[15]  M. Sanak,et al.  Eicosanoid mediator profiles in different phenotypes of nonsteroidal anti‐inflammatory drug‐induced urticaria , 2019, Allergy.

[16]  William Lenis,et al.  HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia , 2019, BMC Infectious Diseases.

[17]  A. Morris,et al.  Shared Genetic Risk Factors Across Carbamazepine‐Induced Hypersensitivity Reactions , 2019, Clinical pharmacology and therapeutics.

[18]  S. Benjaponpitak,et al.  Association of HLA genotypes with Beta-lactam antibiotic hypersensitivity in children. , 2019, Asian Pacific journal of allergy and immunology.

[19]  P. Demoly,et al.  A EAACI drug allergy interest group survey on how European allergy specialists deal with β‐lactam allergy , 2019, Allergy.

[20]  C. Camargo,et al.  Identification of Inpatient Allergic Drug Reactions Using ICD-9-CM Codes. , 2019, The journal of allergy and clinical immunology. In practice.

[21]  Yoshiro Saito,et al.  HLA Alleles and CYP2C9*3 as Predictors of Phenytoin Hypersensitivity in East Asians , 2018, Clinical pharmacology and therapeutics.

[22]  Claude Thermes,et al.  The Third Revolution in Sequencing Technology. , 2018, Trends in genetics : TIG.

[23]  J. Perkins,et al.  Polymorphisms in CEP68 gene associated with risk of immediate selective reactions to non-steroidal anti-inflammatory drugs , 2018, The Pharmacogenomics Journal.

[24]  Lin Zhang,et al.  Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: A meta-analysis , 2018, Seizure.

[25]  M. Whirl‐Carrillo,et al.  Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update , 2018, Clinical pharmacology and therapeutics.

[26]  S. Manzi,et al.  HLA-A*31:01 and Oxcarbazepine-Induced DRESS in a Patient With Seizures and Complete DCX Deletion , 2018, Pediatrics.

[27]  W. Aekplakorn,et al.  Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients , 2018, Journal of immunology research.

[28]  C. C. Cardoso,et al.  Polymorphism of IL10, IL4, CTLA4, and DAO Genes in Cross‐Reactive Nonsteroidal Anti‐inflammatory Drug Hypersensitivity , 2018, Journal of clinical pharmacology.

[29]  C. Sukasem,et al.  Association of HLA-A and HLA-B Alleles with Lamotrigine-Induced Cutaneous Adverse Drug Reactions in the Thai Population , 2017, Front. Pharmacol..

[30]  M. Pirmohamed,et al.  Cost effectiveness analysis of HLA-B*58: 01 genotyping prior to initiation of allopurinol for gout , 2017, Rheumatology.

[31]  H. Chuang,et al.  Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions , 2017, The Journal of Rheumatology.

[32]  D. Margolis,et al.  HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects , 2017, BMC Infectious Diseases.

[33]  C. Sukasem,et al.  Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions , 2017, European Journal of Clinical Pharmacology.

[34]  P. Deloukas,et al.  Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population , 2017, The Journal of antimicrobial chemotherapy.

[35]  J. Perkins,et al.  Pharmacogenomics of Prostaglandin and Leukotriene Receptors , 2016, Front. Pharmacol..

[36]  Michelle Whirl-Carrillo,et al.  Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC) , 2016, Genetics in Medicine.

[37]  Teri E. Klein,et al.  Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC) , 2016, J. Am. Medical Informatics Assoc..

[38]  Sherri Calvo,et al.  Information Needs in the Precision Medicine Era: How Genetics Home Reference Can Help , 2016, Interactive journal of medical research.

[39]  C. Ng,et al.  Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population , 2016, The Pharmacogenomics Journal.

[40]  R. Bruggmann,et al.  Clinical sequencing: is WGS the better WES? , 2016, Human Genetics.

[41]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA‐B) genotype and allopurinol dosing: 2015 update , 2016, Clinical pharmacology and therapeutics.

[42]  J. Perkins,et al.  Association study of genetic variants in PLA2G4A, PLCG1, LAT, SYK, and TNFRS11A genes in NSAIDs-induced urticaria and/or angioedema patients. , 2015, Pharmacogenetics and genomics.

[43]  M. Lee,et al.  Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study , 2015, BMJ : British Medical Journal.

[44]  M. Gutiérrez,et al.  Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients. , 2015, Tissue antigens.

[45]  J. Perkins,et al.  Genetic variants in arachidonic acid pathway genes associated with NSAID-exacerbated respiratory disease. , 2015, Pharmacogenomics.

[46]  A. Romano,et al.  A non-synonymous polymorphism in galectin-3 lectin domain is associated with allergic reactions to beta-lactam antibiotics , 2015, The Pharmacogenomics Journal.

[47]  T. Craig,et al.  HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese , 2015, Asia Pacific allergy.

[48]  G. Novelli,et al.  A Pharmacogenetics Study in Mozambican Patients Treated with Nevirapine: Full Resequencing of TRAF3IP2 Gene Shows a Novel Association with SJS/TEN Susceptibility , 2015, International journal of molecular sciences.

[49]  Nathorn Chaiyakunapruk,et al.  Association of HLA-B*5701 genotypes and abacavir-induced hypersensitivity reaction: a systematic review and meta-analysis. , 2015, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[50]  Shin-Seok Lee,et al.  Cost‐Effectiveness Analysis of HLA–B5801 Genotyping in the Treatment of Gout Patients With Chronic Renal Insufficiency in Korea , 2015, Arthritis care & research.

[51]  J. Madrigal,et al.  The frequency of HLA-B(∗)57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica. , 2014, Human immunology.

[52]  T E Klein,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing , 2014 .

[53]  V. Garg,et al.  HLA-B∗ 1502 is associated with carbamazepine induced Stevens-Johnson syndrome in North Indian population. , 2014, Human immunology.

[54]  Lei Shang,et al.  Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants , 2014, Proceedings of the National Academy of Sciences.

[55]  M. Pirmohamed,et al.  CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations , 2014, The Journal of antimicrobial chemotherapy.

[56]  M. Mockenhaupt,et al.  Management of nonimmediate hypersensitivity reactions to drugs. , 2014, Immunology and allergy clinics of North America.

[57]  T. Klein,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA‐B Genotype and Abacavir Dosing: 2014 Update , 2014, Clinical pharmacology and therapeutics.

[58]  C. Flores,et al.  Variants of CEP68 Gene Are Associated with Acute Urticaria/Angioedema Induced by Multiple Non-Steroidal Anti-Inflammatory Drugs , 2014, PloS one.

[59]  R. Hui,et al.  Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations. , 2014, Journal of dermatological science.

[60]  E. Génin,et al.  HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis , 2013, The Pharmacogenomics Journal.

[61]  M. Gonçalo,et al.  HLA‐B*58:01 is a risk factor for allopurinol‐induced DRESS and Stevens–Johnson syndrome/toxic epidermal necrolysis in a Portuguese population , 2013, The British journal of dermatology.

[62]  A. Romano,et al.  Allergy to betalactams and nucleotide‐binding oligomerization domain (NOD) gene polymorphisms , 2013, Allergy.

[63]  P. Kwan,et al.  HLA‐B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese , 2013, Epilepsia.

[64]  H. Shin,et al.  Genome-wide association study of aspirin-exacerbated respiratory disease in a Korean population , 2013, Human Genetics.

[65]  C. Flores,et al.  Genetic variants of the arachidonic acid pathway in non‐steroidal anti‐inflammatory drug‐induced acute urticaria , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[66]  C. Rondón,et al.  The Diamine Oxidase Gene Is Associated with Hypersensitivity Response to Non-Steroidal Anti-Inflammatory Drugs , 2012, PloS one.

[67]  M. Ingelman-Sundberg,et al.  Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects , 2012, The Pharmacogenomics Journal.

[68]  A. Romano,et al.  Biological and genetic determinants of atopy are predictors of immediate‐type allergy to betalactams, in Spain , 2012, Allergy.

[69]  J. Xuan,et al.  HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese. , 2012, Pharmacogenomics.

[70]  Hailing Qiao,et al.  Polymorphisms of STAT6 and specific serum IgE levels in patients with penicillin allergy. , 2012, International journal of clinical pharmacology and therapeutics.

[71]  Yuan-Tsong Chen,et al.  Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. , 2012, The Journal of allergy and clinical immunology.

[72]  J. McCluskey,et al.  Immune self-reactivity triggered by drug-modified HLA-peptide repertoire , 2012, Nature.

[73]  K. Shianna,et al.  Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions. , 2012, Pharmacogenomics.

[74]  Yuan-Tsong Chen,et al.  Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. , 2011, The Journal of allergy and clinical immunology.

[75]  J. Morioka,et al.  Thromboxane A2 receptor +795T>C and chemoattractant receptor-homologous molecule expressed on Th2 cells -466T>C gene polymorphisms in patients with aspirin-exacerbated respiratory disease. , 2011, Molecular medicine reports.

[76]  N. Chaiyakunapruk,et al.  Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis , 2011, BMC Medical Genetics.

[77]  Yi-wu Shi,et al.  Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population. , 2011, Basic & clinical pharmacology & toxicology.

[78]  Hailing Qiao,et al.  Interleukin-18 and IL18 −607A/C and −137G/C Gene Polymorphisms in Patients with Penicillin Allergy , 2011, The Journal of international medical research.

[79]  Michael R. Johnson,et al.  HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. , 2011, The New England journal of medicine.

[80]  Chen-Yang Shen,et al.  Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. , 2011, The New England journal of medicine.

[81]  Yusuke Nakamura,et al.  Genome-wide association study identifies HLA-A ∗ 3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population , 2022 .

[82]  Y. Ye,et al.  Association of thromboxane A2 receptor (TBXA2R) gene polymorphism in patients with aspirin‐intolerant acute urticaria , 2011, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[83]  Dong Zhou,et al.  Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population , 2010, Epilepsy Research.

[84]  H. Shin,et al.  Genome-Wide and Follow-Up Studies Identify CEP68 Gene Variants Associated with Risk of Aspirin-Intolerant Asthma , 2010, PloS one.

[85]  H. Shin,et al.  Association of PTGER gene family polymorphisms with aspirin intolerant asthma in Korean asthmatics. , 2010, BMB reports.

[86]  M. King,et al.  Genetic Heterogeneity in Human Disease , 2010, Cell.

[87]  M. Muramatsu,et al.  HLA Class I markers in Japanese patients with carbamazepine‐induced cutaneous adverse reactions , 2010, Epilepsia.

[88]  D. Goldstein.  Common genetic variation and human traits. , 2009, The New England journal of medicine.

[89]  S. Tiamkao,et al.  Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population , 2009, Pharmacogenetics and genomics.

[90]  F. Collins,et al.  Potential etiologic and functional implications of genome-wide association loci for human diseases and traits , 2009, Proceedings of the National Academy of Sciences.

[91]  Hailing Qiao,et al.  Polymorphisms and haplotype analysis of IL-4Rα Q576R and I75V in patients with penicillin allergy , 2009, European Journal of Clinical Pharmacology.

[92]  P. Bousquet,et al.  Update on the evaluation of hypersensitivity reactions to betalactams. , 2009, Allergy.

[93]  P. G. Choe,et al.  Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[94]  C. Sotozono,et al.  HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2008, Pharmacogenomics.

[95]  Howard L McLeod,et al.  Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. , 2008, Pharmacogenomics.

[96]  J. Schloss,et al.  How to get genomes at one ten-thousandth the cost , 2008, Nature Biotechnology.

[97]  Na Gao,et al.  Relationships between specific serum IgE, IgG, IFN-γ level and IFN-γ, IFNR1 polymorphisms in patients with penicillin allergy , 2008, European Journal of Clinical Pharmacology.

[98]  A. Romano,et al.  Association of tumor necrosis factor-α –308G>A polymorphism with IgE-mediated allergy to betalactams in an Italian population , 2008, The Pharmacogenomics Journal.

[99]  Y. Teo,et al.  Common statistical issues in genome-wide association studies: a review on power, data quality control, genotype calling and population structure , 2008, Current opinion in lipidology.

[100]  S. Mallal,et al.  High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[101]  L. Naldi,et al.  A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs , 2008, Pharmacogenetics and genomics.

[102]  P. Kwan,et al.  Association between HLA‐B*1502 Allele and Antiepileptic Drug‐Induced Cutaneous Reactions in Han Chinese , 2007, Epilepsia.

[103]  Na Gao,et al.  Association of IL-10 level and IL-10 promoter SNPs with specific antibodies in penicillin-allergic patients , 2007, European Journal of Clinical Pharmacology.

[104]  A. Romano,et al.  Gene–gene interactions of IL13 and IL4RA variants in immediate allergic reactions to betalactam antibiotics , 2006, Pharmacogenetics and genomics.

[105]  P. Demoly,et al.  IL‐10 promoter and IL4‐Rα gene SNPs are associated with immediate β‐lactam allergy in atopic women , 2006 .

[106]  M. McElrath,et al.  Abacavir hypersensitivity reaction in primary HIV infection , 2006, AIDS.

[107]  S. Jee,et al.  Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions , 2006, Pharmacogenetics and genomics.

[108]  C. Suh,et al.  Cysteinyl leukotriene receptor 1 promoter polymorphism is associated with aspirin‐intolerant asthma in males , 2006, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[109]  Hailing Qiao,et al.  Polymorphisms of IL–13 and IL–4–IL–13–SNPs in patients with penicillins allergy , 2005, European Journal of Clinical Pharmacology.

[110]  Hailing Qiao,et al.  Relationships between specific serum IgE, cytokines and polymorphisms in the IL‐4, IL‐4Rα in patients with penicillins allergy , 2005, Allergy.

[111]  H. Shin,et al.  Association analysis of cysteinyl-leukotriene receptor 2 (CYSLTR2) polymorphisms with aspirin intolerance in asthmatics , 2005, Pharmacogenetics and genomics.

[112]  A. Roses,et al.  Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. , 2004, Pharmacogenomics.

[113]  P. Demoly,et al.  Diagnosis of nonimmediate reactions to β‐lactam antibiotics , 2004, Allergy.

[114]  Chiara Sabatti,et al.  The use of pedigree, sib-pair and association studies of common diseases for genetic mapping and epidemiology , 2004, Nature Genetics.

[115]  M. Pirmohamed,et al.  Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. , 2004, Pharmacogenetics.

[116]  Yuan-Tsong Chen,et al.  A marker for Stevens–Johnson syndrome , 2004 .

[117]  I. James,et al.  Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[118]  Choon-Sik Park,et al.  HLA association in aspirin-intolerant asthma: DPB1*0301 as a strong marker in a Korean population. , 2004, The Journal of allergy and clinical immunology.

[119]  H. Shin,et al.  Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase , 2004, Human Genetics.

[120]  Masashi Kobayashi,et al.  Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. , 2002, The Journal of allergy and clinical immunology.

[121]  Clive E. Bowman,et al.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir , 2002, The Lancet.

[122]  C. Moore,et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.

[123]  O. Naderer,et al.  Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. , 2001, Clinical therapeutics.

[124]  J. Bousquet,et al.  A revised nomenclature for allergy: An EAACI position statement from the EAACI nomenclature task force , 2001, Allergy.

[125]  J. Bousquet,et al.  A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. , 2001 .

[126]  I. Edwards,et al.  Adverse drug reactions: definitions, diagnosis, and management , 2000, The Lancet.

[127]  M. Sanak,et al.  Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. , 2000, American journal of respiratory cell and molecular biology.

[128]  J. Drazen,et al.  5' flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. , 2000, The Journal of allergy and clinical immunology.

[129]  K. Pile,et al.  Aspirin‐induced asthma and HLA‐DRB1 and HLA‐DPB1 genotypes , 1997, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[130]  A. Young,et al.  A polymorphic DNA marker genetically linked to Huntington's disease , 1983, Nature.

[131]  K. Davison,et al.  DRUGS: International Drug Monitoring: The Role of National Centres. , 1973, British Journal of Psychiatry.

[132]  H. Chuang,et al.  Utility of human leukocyte antigen-B*58: 01 genotyping and patient outcomes , 2019, Pharmacogenetics and genomics.

[133]  D. Solé,et al.  Angioedema-induced by nonsteroidal anti-inflammatory drugs: a genotype-phenotype correlation in a Brazilian population. , 2019, Journal of investigational allergology & clinical immunology.

[134]  J. Perkins,et al.  Update on the Genetic Basis of Drug Hypersensitivity Reactions. , 2017, Journal of investigational allergology & clinical immunology.

[135]  H. Shin,et al.  Genetic variants of the gasdermin B gene associated with the development of aspirin-exacerbated respiratory diseases. , 2017, Allergy and asthma proceedings.

[136]  A. Romano,et al.  HLA-DRA variants predict penicillin allergy in genome-wide fine-mapping genotyping. , 2015, The Journal of allergy and clinical immunology.

[137]  P. Demoly,et al.  IL-10 promoter and IL4-Ralpha gene SNPs are associated with immediate beta-lactam allergy in atopic women. , 2006, Allergy.

[138]  W. Pichler,et al.  Pharmacological interaction of drugs with immune receptors: the p-i concept. , 2006, Allergology international : official journal of the Japanese Society of Allergology.

[139]  R. González-Sarmiento,et al.  Analysis of the leukotriene C4 synthase A-444C promoter polymorphism in a Spanish population. , 2005, The Journal of allergy and clinical immunology.

[140]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[141]  International Human Genome Sequencing Consortium.  Initial sequencing and analysis of the human genome , 2001, Nature.